FGF9 Antibody

• Studies have demonstrated that miR-4317 can suppress Non-small cell lung cancer (NSCLC) cell growth and metastasis by targeting FGF9 and CCND2. These findings suggest that miR-4317 could serve as a potential non-invasive biomarker and therapeutic target for NSCLC. PMID: 30227870
• Research has established that mutations in FGF9 are associated with craniosynostosis in humans, confirming that FGF9 mutations can cause multiple synostoses. PMID: 28730625
• Forced expression of miR-187 has been shown to inhibit the subcutaneous growth of cervical cancer cells in nude mice. FGF9 was identified as the downstream target of miR-187 in cervical cancer cells. PMID: 28849071
• Data suggests that homodimerization regulates the receptor binding specificity of FGF9 by maintaining the concentration of active FGF9 monomers at a level that is sufficient for normal FGFR "c" isoform binding/signaling but insufficient for illegitimate FGFR "b" isoform activation. Mutations in the N or C-terminus of FGF9 shift the ligand equilibrium towards active monomers, leading to off-target binding and activation of FGFb. PMID: 28757146
• Upregulation of FGF9 or downregulation of miR-372-3p significantly reduced lung squamous cell carcinoma (LSCC) cell growth, mitosis, and invasion. MiR-372-3p enhanced LSCC cell proliferation and invasion by inhibiting FGF9. PMID: 28440022
• Research findings indicate that fibroblast growth factor 9 (FGF9) may provide anti-apoptotic function and serve as a novel independent marker for evaluating gastric cancer (GC) prognosis. PMID: 27166269
• CCND1 mRNA expression is increased by FGF9 in bovine theca cells and granulosa cells. PMID: 27816766
• Current data suggests that non-natural FGFR2 ligands, such as FGF10 and FGF19, are significant factors in the pathophysiology of Aspert syndrome. PMID: 27339175
• In colorectal cancer cell lines overexpressing FGF9, FGF9 overexpression induced strong resistance to anti-EGFR therapies through enhanced FGFR signaling. This resistance was reversed by the administration of an FGFR inhibitor. PMID: 26916220
• FGF9 and FGF18 have been shown to enhance the migratory capacities of human lung fibroblasts, and FGF9 actively regulates matrix metalloproteinase activity in idiopathic pulmonary fibrosis. PMID: 26773067
• Research concludes that the S99N mutation in Fgf9 causes multiple synostoses syndrome (SYNS) by disrupting joint interzone formation. These results further emphasize the critical role of Fgf9 during embryonic joint development. PMID: 28169396
• Studies have identified FGF9 as a target of DICER1 in lung epithelium, functioning as an initiating factor for pleuropulmonary blastoma. PMID: 25978641
• Data suggests that expressing human FGF9 in the kidney subcapsular space of female BALB/c mice leads to rapid local tumor expansion. PMID: 26183774
• FGF9 was found to be strongly expressed in CAFs compared to NGFs, consistent with microarray data indicating that FGF9 is a novel growth factor overexpressed in Cancer-associated fibroblasts. PMID: 25925261
• The relative levels of FGF9 in comparison to other members of the FGF family may be crucial for understanding vulnerability or resilience in affective disorders. PMID: 26351673
• Research has shown that Kl treatment impairs Nodal mRNA expression and Fgf9-mediated Nanos2 induction, reinforcing the antagonistic effect of these two growth factors on the meiotic fate of male germ cells. PMID: 25766327
• Data indicates that FGF9 can initiate a complex astrocytic response predicted to hinder remyelination while concurrently stimulating microglial/macrophage recruitment in multiple sclerosis lesions. PMID: 25907862
• FGF9 expression is associated with a poor prognosis in lung cancer. PMID: 24239165
• MAP3K1 mutations disrupt the balance in sex-determining pathways by downregulating SOX9 and FGF9. PMID: 24135036
• Data demonstrates that the FGF9 IRES functions as a cellular switch to activate FGF9 protein synthesis during hypoxia, a likely mechanism underlying FGF9 overexpression in cancer cells. PMID: 24334956
• FGF9 has been proven to be a direct target of miR-26a. PMID: 24015269
• FGF9 may contribute to epithelial-to-mesenchymal transition and invasion by inducing VEGF-A expression in prostate cancer cells. PMID: 24511001
• In addition to its role in sex determination, FGF9 is expressed in postnatal Leydig cells and is involved in cell-to-cell interaction of testicular function. Abnormal expression of testicular FGF9 is associated with SCOS. PMID: 24011613
• Research shows that FGF9 protein levels increase in regions of active cellular hyperplasia, metaplasia, and fibrotic expansion of idiopathic pulmonary fibrosis lungs. PMID: 23797050
• The importance of Fgf9 in hair follicle regeneration suggests its potential for therapeutic use in humans. PMID: 23727932
• Neither DMRT1 nor FGF9 abnormalities are frequently involved in dysgenetic male gonad development in patients with non-syndromic 46,XY disorder of sex development. PMID: 22939835
• The FGF9(S99N) monomer preferentially binds to the FGFR3c receptor to form an inactive complex, leading to impaired FGF signaling. This impaired FGF signaling is believed to be a potential cause of synostoses syndrome, highlighting the essential role of FGF9 in normal joint development. PMID: 22920789
• These findings suggest that FGF9 can stimulate proliferation and invasion in prostate cancer cells, potentially making FGF9 a predictive factor for recurrence after radical prostatectomy. PMID: 22006051
• Fibroblast growth factor 9 was also overexpressed in all serous ovarian tumors, with a greater than 1000-fold increase in gene expression in 4 tumors. PMID: 21666490
• Microvessels formed in the presence of FGF9 had enhanced capacity to receive flow and were vasoreactive. PMID: 21499246
• FGF9 is an autocrine estromedin endometrial stromal growth factor that plays roles in cyclic proliferation of uterine endometrial stroma. PMID: 12072406
• The proliferative capability of endometriotic stromal cells during menstruation when ovarian 17 beta-estradiol is at its lowest may be mediated, in part, by autocrined estrogen-stimulated expression of FGF-9 and its receptors. PMID: 14602803
• Recombinant human FGF-9 signaling enhances intrinsic osteogenic potential by selectively expanding committed chick embryo osteogenic cell populations and inversely regulating bone morphogenetic protein 2 (BMP-2) and noggin gene expression. PMID: 15780951
• Mesothelial and epithelial transgenic FGF9 directs lung development by regulating mesenchymal growth and the pattern and expression levels of mesenchymal growth factors that signal back to the epithelium. PMID: 16540513
• These findings may provide a molecular framework for considering roles for PGE2 in FGF-9-related embryonic development and/or human diseases. PMID: 16982695
• Polymorphic microsatellite in the 3'-UTR of FGF9 in patients with Gonadal dysgenesis. PMID: 17154280
• FGF9 mutant tumors exhibited normal membranous beta-catenin expression and no mutation in the beta-catenin gene. PMID: 18165946
• Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling. PMID: 18593907
• Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. PMID: 18618013
• This study excluded microdeletions on the critical region as a common cause of Moebius syndrome and ruled out the FGF9 gene. PMID: 19460469
• Data demonstrates that homodimerization autoregulates FGF9 and FGF20's receptor binding and concentration gradients in the extracellular matrix. PMID: 19564416
• Data reveals a previously uncharacterized mutation in FGF9 as one of the causes of Multiple synostoses syndrome, implying a significant role of FGF9 in normal joint development. PMID: 19589401

HGNC: 3687

OMIM: 600921

KEGG: hsa:2254

STRING: 9606.ENSP00000371790

UniGene: Hs.111